Brief: Damora Therapeutics Reports First Quarter 2026 Financial Results
12/05/2026 22:43
May 12 (Reuters) - Damora Therapeutics Inc DMRA.O: DAMORA THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS DAMORA THERAPEUTICS INC - ON TRACK FOR FIRST REGULATORY SUBMISSION FOR DMR-001 IN MID-2026 DAMORA THERAPEUTICS: Q1 EPS $-0.62 Source text: ID:nGNX4bCtTk Further company coverage: DMRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Damora Therapeutics
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Brief: Damora Therapeutics Reports First Quarter 2026 Financial Results
Brief: Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing